arrow
A

Andreas Rimner

University of Freiburg
H指数:58
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

不可切除的III期非小细胞肺癌中,Canakinumab联合化放疗和Durvalumab巩固治疗:CHORUS I/II期试验

2026-09-070
OAAI
Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis

SBRT治疗中央型及超中央型肺肿瘤的疗效与安全性:一项基于PRISMA的系统评价和Meta分析

2026-05-230
OA
Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee

胸腺上皮肿瘤的诊断与管理挑战与争议——国际肺癌研究协会罕见肿瘤委员会胸腺肿瘤分委会

2026-04-100
PRE
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy

新型抗癌药物提高放疗疗效:欧洲放射治疗与肿瘤学会(ESTRO)新型全身治疗与放疗焦点小组立场文件

2026-03-020
PRE
Corrigendum to “Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial” [Radiother. Oncol. 208 (2025) 110907]

勘误 “局部晚期非小细胞肺癌中免疫细胞辐射估计剂量 (EDRIC) 的影响: 多中心随机PET计划试验的二次分析” [Radiother. Oncol. 208 (2025) 110907]

2026-01-160
PRE
International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors

国际胸腺恶性病变兴趣小组:胸腺上皮性肿瘤的标准定义、政策及报告措施

2025-09-260
PRE
Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial

局部晚期非小细胞肺癌中辐射估计剂量对免疫细胞的影响(EDRIC):一项多中心随机PET-Plan试验的二次分析

2025-07-010
OAAI